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Proline is metabolized by its own specialized enzymes with their own tissue and subcellular localizations and mechanisms of
regulation. The central enzyme in this metabolic system is proline oxidase, a ﬂavin adenine dinucleotide-containing enzyme
which is tightly bound to mitochondrial inner membranes. The electrons from proline can be used to generate ATP or can
directly reduce oxygen to form superoxide. Although proline may be derived from the diet and biosynthesized endogenously,
an important source in the microenvironment is from degradation of extracellular matrix by matrix metalloproteinases. Previous
studies showed that proline oxidase is a p53-induced gene and its overexpression can initiate proline-dependent apoptosis by both
intrinsic and extrinsic pathways. Another important factor regulating proline oxidase is peroxisome proliferator activated receptor
gamma (PPARγ). Importantly, in several cancer cells, proline oxidase may be an important mediator of the PPARγ-stimulated
generation of ROS and induction of apoptosis. Knockdown of proline oxidase expression by antisense RNA markedly decreased
these PPARγ-stimulated eﬀects. These ﬁndings suggest an important role in the proposed antitumor eﬀects of PPARγ.M o r e o v e r ,
it is possible that proline oxidase may contribute to the other metabolic eﬀects of PPARγ.
Copyright © 2008 James M. Phang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
PPARγ can regulate inﬂammatory responses to prevent
chronic inﬂammation [1], but more importantly, it plays an
important role in the sensing and regulation of metabolism
[2].Thesefunctions,especiallytheregulationofmetabolism,
maybeinvolvedinthedocumentedabilityofPPARγ tomod-
ulate the malignant phenotype [3]. This aspect of PPARγ
articulates with the resurgence of interest in metabolism and
cancer [4, 5] which has underscored the 50-year old ﬁndings
of Warburg that the metabolism of tumor cells is deranged;
aerobic glycolysis rather than oxidative phosphorylation
is the mode of tumor metabolism [6]. Recent ﬁndings
suggest that many oncogenes and suppressor proteins target
metabolic pathways, and in the context of Warburg’s early
discovery, they form a new, revealing paradigm [7]. The
survival and malignant potential of a tumor are critically
dependent on its adaptation to a variety of stress situations
and nutrient limitations. To generate adequate energy from
the relatively ineﬃcient glycolytic pathway, the ﬂux from
glucose to lactate must be maintained at a high rate [8].
Thus, vascularity and neoangiogenesis as a response not
only to hypoxia but also to the depletion of nutrients play
a critical role in tumor progression [9]. In this context, the
mobilization of proline from the degradation of extracellular
matrix in the tumor microenvironment has come to our
attention. The use of proline as alternative stress substrate
and the regulation of this response by stress signals has been
a focus of our research eﬀort.
2. PROLINE METABOLISM
Proline is the only secondary amino acid incorporated into
protein. Because the alpha nitrogen is contained within a
pyrrolidine ring, proline cannot be metabolized by generic
amino acid enzymes, that is, aminotransferases, decarboxy-
lases, and racemases [10, 11]. Instead, a special family of
enzymesevolvedwiththeirownsubcellularlocalizationsand
mechanisms of regulation. There is a little overlap between
the activity of these enzymes and that for generic amino
acids. Thus, the metabolic system is distinct and can be
responsive to special metabolic requirements. The enzymes2 PPAR Research
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Figure 1: Proline metabolic pathway. Abbreviations: PRO, proline;
P5C, Δ1-pyrroline-5-carboxylate; GLU, glutamate; GSA, glutamic-
gamma-semialdehyde; ORN, ornithine. Enzyme names not shown:
A, P5C Synthase; B, P5C dehydrogenase; C, spontaneous; D,
ornithine aminotransferase.
for the proline metabolic scheme had been characterized by
the 1960s and the general system is shown schematically in
Figure 1. Pyrroline-5-carboxylate, in tautomeric equilibrium
with glutamic-γ-semialdehyde, is a central intermediate. It
is not only the committed precursor of proline but also
the immediate product of proline degradation. Importantly,
it is an obligate intermediate bridging the urea cycle and
the tricarboxylic acid cycle and can play an anaplerotic role
for both metabolic cycles [10, 11] .T h ec o m p l e t em e t a b o l i c
system is not present in all tissues.
Theroleofprolineinproteinshasbeencharacterizedand
reviewed by others [12], and the topic is outside the scope
of this review. However, functions beyond its contribution
to proteins have also been recognized in a variety of animal
and plant species. In prokaryotes, proline is thought to have
antioxidant and osmoprotective functions [11]. Regulatory
roles have been proposed for parasitic trematodes although
the mechanisms are not understood [13]. In a variety of
higher plants, proline is thought to be an osmoprotectant
and the metabolism of proline has been linked to the
synthesis of polyphenolic compounds [14]. Proline has been
identiﬁed as a critical metabolic substrate in the initiation
of ﬂight in insects. In addition, insects can detect and are
attracted to proline. The ﬁnding that proline is at high
concentrations in plant ﬂoral nectar has led to the proposal
that proline is the basis of a coevolution to optimize insect-
mediated pollination [15]. During the molecular biological
explosion of the 1990s, the genes for proline metabolism
were cloned from a variety of sources, making possible
studies deﬁning functions for this special metabolic system.
An interesting feature of proline metabolism is that
the interconversions of proline and pyrroline-5-carboxylate
form a proline cycle. Proline oxidase (POX), a.k.a. proline
dehydrogenase (PRODH), is tightly bound to mitochondrial
inner membranes (the enzyme will be designated POX, but
the gene will be referred to as PRODH) .T h ee n z y m ei s
a ﬂavoprotein and electrons from proline are passed into
the electron transport chain at site II with cytochrome c
as the electron acceptor [10, 11]. Pyrroline-5-carboxylate,
the product of proline degradation, can be converted to
glutamate and α-ketoglutarate to contribute anaplerotically
to the TCA cycle [11]. However, it is also converted back to
proline by pyrroline-5-carboxylate reductase in the cytosol
to form a metabolic cycle. Coupled by pyridine nucleotides
(NADP/NADPH preferentially over NAD/NADH), the pro-
line cycle forms a metabolic interlock with glucose-6-
phosphate dehydrogenase and the pentose phosphate path-
way and serves as a redox shuttle to convert reducing
potential from the pentose phosphate pathway into an ATP-
generating system in mitochondria [16–18]. The magnitude
of ATP generation, however, is small compared to the TCA
cycle and oxidative phosphorylation. The glycolytic pathway,
with optimized ﬂux, also can generate ATP more eﬃciently.
Thus, the contribution of the proline cycle to redox and
energetics was considered trivial previously. However, as
the mechanisms for upregulating POX were elucidated, it
becameclearthatthesystemservesasanimportantaccessory
source for energy under stress conditions.
Proline is available from dietary proteins and can be
biosynthesized from either glutamate or ornithine [10,
11]. However, an abundant source is from degradation
of collagen in the extracellular matrix, connective tissue,
and bone [19]. Since 25% of the residues in collagen is
either proline or hydroxyproline and collagen is the most
abundant (by mass) protein in the body, it serves as an ample
reservoir of proline. Additionally, matrix metalloproteinases
(MMPs), the family of enzymes which degrade collagen
and other proteins in the extracellular matrix, are markedly
upregulated under a variety of conditions. Importantly,
upregulation of MMPsoccurs during tumor progression and
invasion [20, 21] as well as during inﬂammation and wound
healing [22, 23]. MMP upregulation has been considered an
important physical component of invasion, that is allowing
for tumor cells to escape from their basement membrane
site and migrate through tissue. Recently, it has been shown
that a variety of biologically active factors are released from
binding sites on ECM with activation of the MMPs [24].
However, the utilization of proline or hydroxyproline as a
source of metabolic substrate has not been considered. That
degradation of collagen occurs during carcinogenesis in the
skin tumor model has been convincingly demonstrated [25].
Recently, using breast and prostate cancer xenografts and
novel imaging methodology, investigators have shown that
hypoxia mediates collagen ﬁber breakdown and restructur-
ing [26].
3. POX AND APOPTOSIS
P53 is considered the most important cancer suppressor
protein [27]. It is mutated in 85% of all human tumors
and germ-line mutations in p53 result in the Li-Fraumeni
syndrome, a familial syndrome with predisposition to early
cancers in a variety of tissues [28]. To screen for p53 target
genes, Polyak et al. [29] used an adenoviral-p53 expression
construct and serial analysis of gene expression. Only 14 out
of 7202 genes monitored were induced more than 7-fold,James M. Phang et al. 3
and POX was one of these and designated as p53-induced
gene-6 (PIG6). Using a construct where POX expression
was under the control of tetracycline, the overexpression of
POX produced proline-dependent ROS [30] and induced
proline-dependent apoptosis [31–35]. Subsequently, it was
shown that POX overexpression produced its eﬀects through
generation of proline-dependent mitochondrial superoxide
(Figure 2)[34].Itisthissuperoxidewhichplaysacriticalrole
in signaling to produce not only the release of cytochrome
c from mitochondria and the activation of the caspases
in the intrinsic (mitochondrial) limb of programmed cell
death,butalsoitactivatedtheextrinsic(deathreceptor)limb
by increasing the production of TRAIL [35]. A number of
other signaling systems respond to POX-mediated signaling
including downregulation of MEK/ERK phosphorylation
[35], downregulation of COX-2 with decreased PGE2 pro-
duction, and blockade of the progression through the cell
cycle [36].
The ﬁndings from the tissue culture system have been
translated into an animal model. In studies using DLD-POX
cells to form xenografts in athymic mice, the expression
of POX markedly inhibited tumor formation [37]. In mice
given doxycycline to suppress POX expression in DLD-POX
cells, or in animals injected with DLD-vector cells, tumors
formed rapidly. By week 2 all these animals developed
palpable tumors and by week 3, the animals had to be
sacriﬁced due to the size of the tumors. By contrast, in mice
without doxycycline in which POX was overexpressed, few
tumors were detected. By week 2, only 1 out of 16 animals
had palpable tumors. Thus, the expression of POX markedly
inhibited the formation of xenografts.
The relevance of these changes in POX was pursued by
immunohistochemical studies in human tissues. Ninety-two
paired normal and cancer tissues from a variety of tumors
were examined using immunohistochemistry. The ﬁndings
were striking from gastrointestinal tumors (stomach, colon,
pancreas)inwhichthe level ofPOXexpression wasmarkedly
decreased or undetectable in 79% of the tumors [36].
We are currently investigating the genetic or epigenetic
mechanism for the decrease in POX expression, but based
on these ﬁndings, we propose that POX is a potential cancer
suppressor protein.
The mechanism for the POX-mediated, proline-depen-
dent generation of superoxide may be due to leakage of
electrons from the electron transport chain, a mechanism
proposed for other sources of mitochondrial superoxide.
However, recent studies from structural biology suggest that
the generation of superoxide is an intrinsic property of the
enzyme.Whiteetal.[38]describedinterestingﬁndingsusing
recombinant Thermus thermophilus POX/PRODH. Unlike
the POX/PRODH from certain prokaryotic species, for
example Escherichia coli, which have a bifunctional enzyme,
embodyingtheactivitiesofPOXandpyrroline-5-carboxylate
dehydrogenase in a single protein, the enzyme from T.
thermophilus is monofunctional and produces pyrroline-5-
carboxylate in a manner similar to the enzyme in animal
tissues, and thus may serve as a good model for human
POX [38]. These workers found that the ﬂavin adenine
dinucleotide is located in a domain exposed to solvent
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Figure 2: Proline oxidase-induced apoptosis. Abbreviations: ROS,
reactive oxygen species; TRAIL, tumor necrosis factor related
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Figure 3: Structure of proline dehydrogenase (proline oxidase)
fromThermusthermophilus.Theﬂavineadeninedinucleotideatthe
active site is shown in yellow. The ﬂexible alpha helix adjacent to
the FAD is shown in violet and blue. Access of the FAD to solvent
O2 allows direct reduction of O2 to form superoxide radicals. The
ﬁgure is used with permission from Dr. Jack Tanner, University of
Missouri-Columbia, and the Journal of Biological Chemistry.
oxygen. Thus, the electrons from proline can be used to
reduce oxygen to superoxide (Figure 3). In addition, they
found an adjacent α-helix which can shield the FAD and
block its access to solvent oxygen. The interpretation of these
ﬁndings includes the intriguing possibility that POX can be
switched from an ATP-generating function to a superoxide-
producing function. Although a number of enzymes have
been proposed as generators of superoxide, these enzymes
are cytosolic (xanthine oxidase) or are associated with cell
membranes (NADPH oxidase) with their own speciﬁed
functions.
These aforementioned functions of POX have been
emphasized for their relevance to cancer, but another func-
tion deserves mention. Proline functions as a neurotrans-
mitter, inhibiting glutamatergic neurons [39]. Additionally,4 PPAR Research
a high-aﬃnity transporter has been discovered and cloned
from the brain [39]. The relevance to neurological systems
extends to lower species. Mutations in POX/PRODH result
in “sluggishness” in Drosophila melanogaster [40] and the
PRO/Re mice, defective in POX/PRODH, exhibit “gating”
defects, a functional neurologic defect [41]. In humans,
mutationsinPRODH havebeenassociatedwithriskforearly
schizophrenia [42]. Although there has been a number of
studiessupportingorcontradictingthisconclusion,evidence
supports the relevance of POX mutations. It has been
shown that the mutations in PRODH associated with the
neuropsychiatric syndrome have a biochemical phenotype
with markedly decreased activity in the enzyme [43].
4. REGULATION OF POX
The induction of POX by p53 suggested that it served
special functions and was not simply a “housekeeping
enzyme.” To screen for potential regulators, Pandhare et
al. [44] made a POX-promoter, luciferase-reporter con-
struct, and cotransfected a variety of transcriptional factors
corresponding to binding sites identiﬁed in the PRODH
promoter. Although Jun, Fos, and p65 of NF-κBp r o d u c e d
modest stimulatory eﬀects (<2-fold), a marked activation
of the PRODH promoter was observed with cotransfection
of PPARγ. This ﬁnding was interesting, indeed, since this
pleiotropic factor not only plays an important role in
metabolism [2], especially of adipocytes, but also it is
an important modulator of inﬂammatory responses [1].
The wide use of the thiazolidinediones (TZDs) in the
management of hyperglycemia in type 2 diabetes mellitus is
an example of the former [45]. For the latter, some inves-
tigators have suggested that PPARγ provides a mechanism
to downregulate inﬂammatory stress responses and avoid
the pathologic consequences of chronic inﬂammation [46].
Attracting considerable attention recently is the ﬁnding in
a variety of cultured cancer cells that TZDs will block cell
proliferation and induce apoptosis [47–49]. Epidemiologic
data from patients with type 2 DM treated with TZDs
suggest that these ligands of PPARγ a r ep r o t e c t i v ea g a i n s t
lung cancer but not against colon or prostate cancer [50].
With the impressive in vitro data and suggestive ﬁndings
from epidemiology, oncologists have proposed that PPARγ
is an attractive target for cancer treatment.
5. MECHANISM OF TZDs IN INDUCING PRODH
Pandhare et al. [44] showed that cotransfection of PPARγ
activated the PRODH promoter 8-fold, and troglitazone,
a widely used TZD before it was taken oﬀ the market
because of side eﬀects, further increased the magnitude of
this activation. The combination of PPARγ expression and
troglitazone treatment activated the PRODH promoter more
than 10-fold (Figure 4). The eﬀect could be generalized to
a variety of colorectal cancer cells and could be elicited by
fourdiﬀerentTZDs.ThattroglitazoneinducedPOXthrough
aP P A R γ mediated binding to the peroxisomal proliferator
response element was shown using several methods. First,
anelectrophoreticshiftmobilityassayshowedatroglitazone-
stimulated formation of a nuclear complex with the labeled
PPRE sequence from the PRODH promoter. That PPARγ
was present in this complex was shown with chromatin
immunoprecipitation assays. In this assay, formaldehyde was
used to cross-link DNA-protein complexes and then the
DNA was sheared by sonication. After immunoprecipitation
with speciﬁc anti-PPARγ antibody, the PPRE sequences of
the PRODH promoter were ampliﬁed using polymerase
chain reaction.
Although these studies showed that PPARγ and its
pharmacologic ligands are directly involved in the activation
of the PRODH promoter, the integration of signaling by
the PPARγ assembly to physiologically regulate PRODH
expression may be more complex. The interaction with
retinoid-X receptors (RXR) is a requisite for PPARγ function
[51]. Moreover, a number of coactivators interact with
liganded PPARγ and RXR to form an active transcriptional
complex. These include steroid receptor PPARγ-coactivator-
1 (PGC-1) and steroid receptor coactivator-1 (SRC-1) [52].
The speciﬁc coactivator may depend on the cell type and
stimuli. In the context of metabolism, PGC-1 may be
especially relevant since it responds to signaling from other
metabolism-regulating hormones and cytokines [53]. The
speciﬁc eﬀect of these coactivators on PRODH expression,
however, has not been elucidated, but it is an area of
emphasis of our current work.
6. CONTRIBUTION OF POX TO THE PPARγ
EFFECTS ON ROS AND APOPTOSIS
The discovery that PPARγ has a marked inhibitory eﬀect
on cultured cancer cells stimulated a large number of
studies using a variety of cancer cells. The TZDs augmented
diﬀerentiation, slowed proliferation, and induced apoptosis.
Although this eﬀect was generally observed, there were a
few reports of TZDs actually stimulating the growth of
certain cultured cancer cells [54]. Nevertheless, the prepon-
derance of studies showed that TZDs inhibited growth [47–
49]. Although the mechanism of this eﬀect was not well
understood, several investigators found that TZDs induced
the generation of ROS, and they concluded that ROS was the
mechanism for inducing apoptosis as has been reported for
many experimental models. The actual mechanism by which
ROS production was induced by TZDs, however, remained
unknown.
Since POX is a p53-induced gene and has been estab-
lished as a mechanism for generating superoxide that
initiates apoptosis, the PPARγ induction of POX raised
the attractive hypothesis that POX may be involved in the
apoptotic mechanism observed with the TZDs. To answer
this question, Pandhare et al. [44] showed that in colorectal
cancer cells, troglitazone not only induced POX, but also
markedly increased the production of ROS as has been
shown by others in other cultured cells. More importantly,
the knockdown of POX with antisense RNA markedly
decreased the generation of troglitazone-stimulated ROS.
These studies strongly suggested that the ROS presumed to
be the mechanism for TZD-stimualted apoptosis was due, at
least in part, to its induction of POX. Thus, POX plays anJames M. Phang et al. 5
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Figure 4: Induction of proline oxidase by PPARγ and its pharmacologic ligand, troglitazone. (a) Activation of the POX promoter using a
luciferase reporter assay. HEK 293 colorectal cancer cells were transfected with equivalent amounts of cDNA of PPARγ or vector plasmid as
control. The cells were also transfected with POX-Luc and pRL-null. Troglitazone (25 μM) or Me2SO in control was added after 10 hours
as indicated. At 24–36 hours after transfection, the cell lysates were harvested, and the POX promoter luciferase activity was determined
using the Dual Luciferase Assay kit. (b) Troglitazone increases the binding of PPARγ to the PPRE in the POX promoter. HCT 116 colorectal
cancer cells were treated with or without 25 μM troglitazone for 36 hours and nuclear extracts were prepared. The binding of PPARγ to
the PPRE was evaluated by an electrophoretic mobility shift analysis assay using the double-stranded POX-PPRE oligonucleotide probe.
Unlabeled POX-PPRE probe (100x) was used as a competitor (lane 4). (c) Chromatin immunoprecipitation assay of the POX promoter in
troglitazone-treated HCT 116 cells. HCT 116 cells were incubated with 1% formaldehyde to ﬁx protein-DNA complexes. DNA was sheared
by sonication. Soluble chromatin-DNA complexes were immunoprecipitated using PPARγ antibody and immunoprecipitates were analyzed
by PCR with speciﬁc primers for the POX promoter region containing the POX-PPRE.
important role in the apoptotic eﬀect of TZDs, at least in
tissue culture. This ﬁnding was soon conﬁrmed by others.
Working with nonsmall cell lung cancer cells, Kim et al.
[55] showed that rosiglitazone induced apoptosis through
an ROS-dependent mechanism, and that the induction of
POX by rosiglitazone played a critical role in the production
of apoptosis. These are exciting ﬁndings but require further
corroboration and extension to other cultured cancer cells.
The eﬀects of TZDs in cultured cells have been extended
to several tumor models in animals and the results are
encouraging. In athymic mice, the growth rates of xenografts
of ovarian, thyroid, and bladder cancer are markedly aﬀected
by a variety of PPARγ-stimulating agents [47–49]. Not only
is tumor growth inhibited but survival of the host animal is
prolonged.Althoughthemechanismunderlyingtheseeﬀects
remains unclear, it appears that the cells in the tumors are
apoptotic perhaps due to decreased expression of COX-2
[56]. Recent work in our laboratory links POX expression to
downregulation of COX-2 [36]. There are direct eﬀects on
t h et u m o ra sw e l la se ﬀects on angiogenesis. There are no
studies of the eﬀects of PPARγ on POX expression in animals
or on the role of POX in mediating the PPARγ-mediated
antitumor eﬀects.
7. PARADOXES AND POSSIBLE SOLUTIONS
The enthusiasm generated by these antitumor eﬀects of
PPARγ and the TZDs was somewhat blunted by the
ﬁnding that in C57Bl/6J-APCMin/+ mice, activation of
PPARγ-mediated signaling promotes rather than inhibits6 PPAR Research
the development of colon tumors [57]. APC is the tumor
suppressor protein in adenomatous polyposis coli and is
an integral part of the Wnt/β-catenin signaling system.
The Min mutation blocks the formation of the tetrameric
complex (APC, axin, GSK-3β, β-catenin) which allows for
phosphorylation of β-catenin leading to its proteasomal
degradation. Accumulated β-catenin translocates into the
nucleus to form transcriptional complexes with TCF/LEF to
induce target genes involved in proliferation [58]. However,
in keeping with the earlier reports that activation of PPARγ
or its ligands had antitumor eﬀects, recent studies have
shown marked reduction in tumor growth or survival of
animals with peritoneal carcinomatosis with various PPARγ
ligands. These recent studies include ovarian cancers [47],
anaplastic thyroid carcinomas [48], and bladder tumors
[49]. Thus, the debate continues: “. . . the action of PPARγ
on cell cycle, proliferation, diﬀerentiation, and apoptosis
seems to depend on the cell type and/or the mutational
events that predispose tissue to cancer development” [58].
The importance of coactivators or corepressors cannot be
overemphasized. Interactions with and contributions of the
microenvironment must also be considered in understand-
ing these diﬀerent eﬀects.
A common target of these signaling pathways is the
matrix metalloproteinases (MMP) [59, 60]. Diﬀerential
eﬀects on these enzymes may explain, in part, the vari-
ability in the aforementioned eﬀects of PPARγ activa-
tion. Increased PPARγ signaling will downregulate MMP
whereas certain MMP are target genes of β-catenin/TCF-
LEF. The transcriptional system constitutively upregulated
by the APCMin mutation increases the expression of MMP-
7. Just how these mechanisms articulate for regulating
MMP remains unclear. However, in the context of the
aforementioned induction of POX by PPARγ, the diﬀerential
eﬀects on MMP may be relevant. In a given experimental
model, the availability of ECM and the eﬀects on MMP
may determine the relative availability of proline as a
stress substrate for POX. Furthermore, the consequences
of POX induction may also be two-edged. Under stim-
ulation of p53, POX can use proline to generate mito-
chondrial superoxide to initiate apoptosis by both intrinsic
and extrinsic pathways [34]. Recent work has shown that
POX overexpression will also blockade the cell cycle [61].
Thus, upregulation of POX in the presence of MMP to
generate free proline will activate antitumor mechanisms.
On the other hand, POX also can generate ATP and
it is upregulated by downregulation of mTOR signaling
under nutrient stress. With the availability of proline,
upregulation of POX can support cell survival [62]. Like
several mediators of metabolic regulators, for example, p53
and PPARγ, POX also can play a two-edged regulatory
role.
8. THE ROLE OF POX IN ANTITUMOR
EFFECTS OF PPARγ
Additional work is needed to translate these ﬁndings in
cultured cancer cells to animal models and eventually to
clinical trials. As a ﬁrst step, studies are being undertaken
to monitor the expression of POX in mice administered
TZDs. Assuming that certain tissues in intact animals will
respond as in cultured cells, the eﬀect of POX upreg-
ulation on spontaneous tumors in that tissue can be
investigated. The inhibition of POX by proline analogues
or the blockade of MMPs, speciﬁcally prolidase, may limit
the availability of proline in that tissue. Also, control
of dietary proline could be important. With the insights
gained by these animal studies, it may be possible to
design clinical trials in which perturbations of the POX-
mediated eﬀects can be pharmacologically attacked as an
adjunct to the use of TZDs or other PPARγ activators.
Furthermore, PPARγ activation with or without POX can be
used in combination with other chemotherapeutic modali-
ties.
9. CONTRIBUTION OF POX TO OTHER
PPARγ-MEDIATED EFFECTS
The consequences of POX induction and its role in PPARγ-
mediated metabolic eﬀects other than that on cancer have
not been explored. However, it is intriguing that the well-
established metabolic eﬀects of PPARγ could be mediated in
part by induction of POX. Nevertheless, the known eﬀects
of POX and PPARγ invite speculation, but these speciﬁc
questions have not been experimentally addressed. Thus,
these questions remain in the realm of future plans. Of
special consideration are the following eﬀects of PPARγ:
(1) increased insulin sensitivity, (2) decreased inﬂammation,
and (3) increased osteopenia.
There are potential links between degradation of proline
and insulin-related metabolic eﬀects. Certainly, POX uses
proline to generate intermediates for anaplerosis of the TCA
cycle which could make oxidative metabolism more eﬃcient.
Investigators have cited the importance of these interme-
diates as building blocks rather than as energy substrates.
Furthermore,themetabolicinterlockoftheprolinecycleand
glucose metabolism through the pentose phosphate pathway
could aﬀect insulin sensitivity since it opens an alternative
pathway for glucose metabolism. Thus, glucose would not
only be metabolized by oxidative phosphorylation in the
TCA cycle and converted to lactate by glycolysis, but also
would be converted to CO2 by interconversions and cycling
through the pentose phosphate shunt.
The PPARγ signaling pathway is frequently considered as
a response to inﬂammatory stress, that is, to prevent chronic
inﬂammation. Inﬂammatory cells such as macrophages will
respond to inﬂammatory signals such as prostaglandins and
this will induce POX in macrophages and induce apoptosis.
Furthermore, COX-2 may be regulated by the expression of
POX and the generation of proline-mediated ROS [36].
The ﬁnal metabolic consideration is the demonstrated
eﬀects in animals and in humans that TZDs will result
in osteopenia [63]. From histologic and metabolic stud-
ies, PPARγ appears to decrease osteogenesis and increase
osteoloysis. There are decreased numbers of osteoblasts and
increased numbers of osteoclasts [64]. Since bone is primar-
ily made up of calciﬁed collagen, it is not surprising that
collagen synthesis is decreased and collagen degradation isJames M. Phang et al. 7
increased.Sincecollagensynthesisrequirestheincorporation
of proline, the degradation of proline by increased POX
would be a biochemical process consistent with osteoclastic
function.
Another interesting area involves a physiologic/patho-
physiologic source of natural ligands for PPARγ, that is,
oxidized low-density lipoproteins (oxLDL). Their precursor,
low-density lipoproteins (LDL) are synthesized in the liver
and are the carriers for 60% of total serum cholesterol,
and they are widely known as the “bad cholesterol.” Recent
studies suggest that LDL is oxidized in human blood and
tissues under various pathological conditions. OxLDL may
be an important player in the development of atheroscle-
rosis, promoting apoptosis in endothelial cells, increasing
proliferation of smooth muscle cells, and upregulating
inﬂammatory signaling in macrophages. The result is the
formation of atheromatous plaques. Mechanisms of oxLDL-
induced eﬀects are being intensively investigated, but there
is a considerable evidence supporting a role for PPARγ
activation [65]. Additionally, oxidized LDL activates p53
[66, 67] and stimulates the formation of mitochondrial ROS
[68] to induce cell death. Since all these mechanisms are
linked to POX activity, it is tempting to speculate that POX
may be involved.
Although oxLDL is mainly associated with atherosclero-
sis, several studies point to the correlation between serum
oxLDL levels and cancer risk in humans [69, 70]. This
prompted us to study the possible role of POX in the
oxLDL-mediated eﬀects on carcinogenic pathways. First, we
transfected breast, prostate, colon, cervical, ovarian, and
lung cancer cell lines with the POX promoter-luciferase
reporter and found that oxLDL treatment activated the POX
promoter in a dose- and time-dependent manner. This eﬀect
was further augmented by the addition of 2.5 mM proline.
We also found that oxLDL treatment increased POX gene
expression as compared to nonoxidized LDL, or a solvent
control [Zabirnyk O and Phang JM, unpublished results].
These preliminary studies suggest a role of proline oxidase
in the oxLDL-mediated eﬀects on PPARγ activation and
initiation of apoptotic cell death.
In summary, POX, a p53-induced gene, is markedly
upregulated by overexpression of PPARγ or by the addi-
tion of TZDs. The eﬀect is generalizable to a variety of
cells and to all the TZDs. The mechanism of this eﬀect
appears to be by transcriptional activation by activating
the POX promoter at the PPRE site. The PPARγ eﬀect
on apoptosis is mediated by the generation of ROS, and
knockdown of POX by siRNA markedly decreases or blocks
the eﬀects of PPARγ on ROS formation and apoptosis
in colorectal cancer cell or nonsmall cell lung cancer
cell, respectively. These ﬁndings suggest that POX may
play a critical role in PPARγ-mediated antitumor eﬀects.
Furthermore, it may oﬀeran explanation for the inconsistent
ﬁndings observed in diﬀerent animal systems. It also may
oﬀer an adjunctive therapeutic approach to optimize the
PPARγ-mediated antitumor eﬀects. Finally, a speculative
proposal for the articulation of POX-dependent metabolic
eﬀects on the metabolic syndrome with PPARγ activation is
presented.
ABBREVIATIONS
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P5C: Δ1-pyrroline-5-carboxylic acid
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